Existing Klarity-C Patients to Have Access to VEVYE for $59 Per Bottle
Harrow, a leading North American eyecare pharmaceutical company, announced an expansion of its VEVYE Access for All program to include patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx, Harrow’s compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access barriers like prior authorization and reimbursement delays, providing free home delivery, and offering a no‑questions-asked, money-back guarantee.1 The VEVYE Access for All program is flexible, allowing patients to choose to use their insurance coverage2 or take advantage of Harrow’s affordable cash price.
Health Technology Insights: Nsight Health and UnisLink Partner to Enhance Healthcare Operations
As a result of announcement, beginning immediately, more than 25,000 patients across the U.S. will be able to convert their Klarity-C prescriptions to VEVYE (cyclosporine ophthalmic solution) 0.1%, an FDA‑approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle (including refills). As a part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer Klarity-C prescriptions to PhilRx in a process that shouldn’t take more than 5 minutes.
Health Technology Insights: Merit Medical Launches the Ventrax Delivery System
“We are pleased to make VEVYE accessible and affordable to Klarity-C patients,” said Mark L. Baum, Chief Executive Officer of Harrow. “The secret to the success of VEVYE Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy. The result is twofold: dry eye patients receive what their doctor prescribes at an affordable price; and for doctors and their staff, choosing VEVYE is an absolute no‑brainer.”
“Pharmaceutical companies have long made promises to tackle the access barriers my colleagues and I encounter when advocating for our patients – especially in the realm of dry eye treatments. Harrow, a company that has consistently brought meaningful innovation to my practice, has delivered once again with VEVYE Access For All,” said Alice Epitropoulos, MD, FACS, Partner and Co-founder of the Eye Center of Columbus. “I often prescribed Klarity-C because it provided exceptional value to my patients, particularly those without insurance or with limited coverage. Now, being able to offer VEVYE at that same affordable price point to some of my dry eye disease patients – without the usual insurance hassles – is a game changer. This is true price transparency and accessibility that simplifies care and supports what matters most: better outcomes.”
“The value proposition here is undeniable,” added Mitchell Jackson, MD, Founder/Medical Director of Jacksoneye and a pioneer in refractive surgery and dry eye management. “My colleagues in ophthalmology and optometry already know about VEVYE’s extraordinary clinical benefits. But how often do we see a pharmaceutical company actually lower costs and pass those savings directly to the patients – all while removing the insurance hurdles that have burdened our practices? Only Harrow. No prior authorizations or step therapy requirements, no surprise bills – just straightforward, reliable access to an excellent medication. It’s the kind of model our healthcare system should be moving toward.”
Health Technology Insights: GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
